Ontario achieves significant savings with oncology biosimilars

The use of oncology biosimilars has led to substantial annual savings in Ontario. In fiscal years 2020/21, 2021/22 and 2022/23, Ontario Health saved an estimated $53 million, $44 million, and $53 million, respectively.